High Frequency of CD4+CXCR5+ TFH Cells in Chronic Hepatitis B Patients
Author Information
Author(s): Feng Junyan Lu, Hua Cong, Qin Ling Zhao, Pingwei Wang, Juan Wang, Ye Li, Wanyu Shi, Xiaodong Jiang, Yanfang Jiang
Primary Institution: Department of Central Laboratory, the Second Part of First Hospital, Jilin University, Changchun, China
Hypothesis
Is there an association between the frequency of CD4+CXCR5+ TFH cells and active immunity in chronic hepatitis B patients?
Conclusion
The study found that a high frequency of CD4+CXCR5+ TFH cells may serve as a biomarker for evaluating the active immune stage in chronic hepatitis B patients.
Supporting Evidence
- The frequency of CD4+CXCR5+ TFH cells in immune-active patients was significantly higher than in immune-tolerant patients and healthy controls.
- Treatment with adefovir dipivoxil reduced the frequency of CD4+CXCR5+ TFH cells in drug-responding patients.
- The percentages of CD4+CXCR5+ TFH cells were positively correlated with serum AST levels in immune-active patients.
Takeaway
This study shows that patients with chronic hepatitis B have more special immune cells called TFH cells, which might help doctors understand how active the disease is.
Methodology
The study used flow cytometry to analyze the frequency of CD4+CXCR5+ TFH cells in patients and healthy controls.
Limitations
The study had a small sample size and lacked functional studies of TFH cells.
Participant Demographics
The study included 23 immune-active patients, 13 immune-tolerant patients, and 12 healthy controls, with no significant differences in age and gender.
Statistical Information
P-Value
0.023
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website